Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vidofludimus (SC12267) 是一种新型的二氢乳清酸脱氢酶 (DHODH) 小分子抑制剂,可在不影响淋巴细胞增殖的条件下抑制IL-17的分泌。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 449 | 现货 | ||
5 mg | ¥ 751 | 现货 | ||
10 mg | ¥ 1,255 | 现货 | ||
50 mg | ¥ 3,775 | 现货 | ||
100 mg | ¥ 4,530 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 581 | 现货 |
产品描述 | Vidofludimus (SC12267) (4SC-101, SC12267) is a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH). |
靶点活性 | DHODH (human):134 nM |
体外活性 | Vidofludimus causes a concentration dependent inhibition of phytohemagglutinin-stimulated PBMC proliferation via the inhibition of pyrimidine de novo synthesis. [1] Vidofludimus attenuates IL-17 secretion from colonic strips by inhibition of STAT3 and NF-κB activation. [2] |
体内活性 | In MRLlpr/lpr mice, Vidofludimus (300 mg/kg, p.o.) reduces systemic autoimmunity and improves Lupus Nephritis. [1] In Rats, Vidofludimus (60 mg/kg, p.o.) effectively reduces macroscopic and histological pathology and the numbers of CD3+ T cells. [2] In a rat model of renal transplantation, Vidofludimus (20 mg/kg, p.o.) prolongs survival, paralleled by amelioration of histologic signs of acute rejection. [3] |
激酶实验 | DHODH inhibition assay: In vitro DHODH inhibition assay mixture contains 50 μM decycloubiquinone, 100 μM dihydroorotate, and 60 μM 2,6-dichloroindophenol. The amount of enzyme is adjusted such that an average slope of approximately 0.2 AU/min will be achieved in the assay for the positive control (eg, without inhibitor). Measurements are conducted in 50 mM TrisHCl, 150 mM KCl, 0.1% Triton X-100, and pH 8.0 at 30°C in a final volume of 1 ml. The components are mixed, and the reaction is started by adding dihydroorotate. The reaction is followed spectrophotometrically by measuring the decrease in absorption at 600 nm for 2 minutes. The assay is linear in time and enzyme concentration. Inhibitory studies are conducted in a standard assay with additional variable amounts of inhibitor. For the determination of the IC50 values (concentration of inhibitor required for 50% inhibition), eight different inhibitor concentrations are applied. Each data point is recorded in triplicates on a single measurement day. |
别名 | SC12267, 4sc-101 |
分子量 | 355.36 |
分子式 | C20H18FNO4 |
CAS No. | 717824-30-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 100 mg/mL (281.4 mM)
Ethanol: 1 mg/mL (2.81 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.814 mL | 14.0702 mL | 28.1405 mL | 70.3512 mL |
DMSO | 5 mM | 0.5628 mL | 2.814 mL | 5.6281 mL | 14.0702 mL |
10 mM | 0.2814 mL | 1.407 mL | 2.814 mL | 7.0351 mL | |
20 mM | 0.1407 mL | 0.7035 mL | 1.407 mL | 3.5176 mL | |
50 mM | 0.0563 mL | 0.2814 mL | 0.5628 mL | 1.407 mL | |
100 mM | 0.0281 mL | 0.1407 mL | 0.2814 mL | 0.7035 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Vidofludimus 717824-30-1 Cell Cycle/Checkpoint DNA Damage/DNA Repair Immunology/Inflammation Metabolism Dehydrogenase DNA/RNA Synthesis Interleukin DHODH SC-12267 fatty liver Inhibitor SC12267 Dihydroorotate Dehydrogenase dihydroorotate dehydrogenase (DHODH) oral 4sc-101 Interleukin Related FXR NR1H4 non-alcoholic fatty liver disease (NAFLD) inflammatory bowel disease (IBD) immunomodulatory farnesoid X receptor (FXR) inhibit SC 12267 inhibitor